Last reviewed · How we verify
TAK-491
At a glance
| Generic name | TAK-491 |
|---|---|
| Also known as | Azilsartan medoxomil, Edarbi |
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure
- Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia) (PHASE1)
- An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension (PHASE3)
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure (PHASE3)
- Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B (PHASE1)
- Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAK-491 CI brief — competitive landscape report
- TAK-491 updates RSS · CI watch RSS
- Takeda portfolio CI